Lymphovascular invasion of colorectal cancer is correlated to SPARC expression in the tumor stromal microenvironment

As an integral component of the microenvironment in colorectal cancer (CRC), stromal cells can influence tumor progression. Found in the extracellular matrix of CRC, secreted protein acidic and rich in cysteine (SPARC) is expressed in stromal and CRC cells. While SPARC's influence on CRC is not clear, we hypothesized that epigenetically regulated SPARC expression in the microenvironment stromal cells of CRC can affect primary CRC progression and is influenced by lymphovascular invasion (LVI). Quantitative immunohistochemistry (IHC) analysis of paraffin-embedded (n=72) from 37 LVI-positive and 35 LVI-negative primary CRCs was performed. MassARRAY sequencing was performed to assess the methylation status of the promoter region in 22 LVI-positive and 20 LVI-negative CRC and to identify specific CpG island(s) regulating SPARC expression. SPARC in CRC cells was not correlated with LVI, whereas SPARC in the microenvironment stromal cells was inversely related to LVI (P < 0.0001). There was a direct relationship between LVI and 6 specific CpG site methylation in the SPARC promoter region of stromal cells (P = 0.017) but not in CRC cells. Stromal SPARC expression inversely correlated with VEGF-A expression in CRC (P = 0.003) and positively correlated with HSP27 expression (P = 0.009). The results suggested that the epigenetic regulation of SPARC expression in tumor cells versus stromal cells of CRC is significantly different. Stromal cell SPARC expression is epigenetically influenced by LVI of CRC tumors, and may play a significant role in primary CRC progression.

[1]  R. Tollenaar,et al.  Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma. , 2010, The American journal of pathology.

[2]  Xiaofeng Peng,et al.  Clinical significance of HSP27 expression in colorectal cancer. , 2010, Molecular medicine reports.

[3]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[4]  I. Witz.  The Tumor Microenvironment: The Making of a Paradigm , 2009, Cancer Microenvironment.

[5]  Yusuke Sato,et al.  Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment , 2009, Cancer Microenvironment.

[6]  D. Royston,et al.  Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma , 2009, The Journal of pathology.

[7]  D. Morton,et al.  CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma , 2009, Clinical Cancer Research.

[8]  S. Groshen,et al.  Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. , 2009, Cancer research.

[9]  M. Tang,et al.  SPARC in cancer biology: its role in cancer progression and potential for therapy. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[10]  T. Barker,et al.  HSP27 mediates SPARC‐induced changes in glioma morphology, migration, and invasion , 2008, Glia.

[11]  H. Putter,et al.  Quantitative analysis of methylation of genomic loci in early-stage rectal cancer predicts distant recurrence. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Owen,et al.  SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response , 2008, British Journal of Cancer.

[13]  C. Brodie,et al.  SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion , 2008, International journal of cancer.

[14]  I. Witz.  Tumor-microenvironment interactions: dangerous liaisons. , 2008, Advances in cancer research.

[15]  Andrea S. Llera,et al.  The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host , 2008, Cancer and Metastasis Reviews.

[16]  A. Longatto-Filho,et al.  Peritumoural, but not intratumoural, lymphatic vessel density and invasion correlate with colorectal carcinoma poor-outcome markers , 2008, Virchows Archiv.

[17]  R. Bjerkvig,et al.  Lymphangiogenesis in colorectal cancer—Prognostic and therapeutic aspects , 2007, International journal of cancer.

[18]  Hans J. Tanke,et al.  The Carcinoma–Stromal Ratio of Colon Carcinoma Is an Independent Factor for Survival Compared to Lymph Node Status and Tumor Stage , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[19]  Hoguen Kim,et al.  Frequent inactivation of SPARC by promoter hypermethylation in colon cancers , 2007, International journal of cancer.

[20]  C. Iacobuzio-Donahue,et al.  Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Putter,et al.  Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Hong Zhang,et al.  Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas , 2006, Molecular Cancer.

[23]  J. Silverman,et al.  Lymphatic microvessel density as prognostic marker in colorectal cancer , 2006, Modern Pathology.

[24]  P. Abbe,et al.  SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. , 2006, Cancer research.

[25]  D. Morton,et al.  Estrogen receptor-α methylation predicts melanoma progression , 2006 .

[26]  J. Ambati,et al.  Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. , 2006, The Journal of clinical investigation.

[27]  Qiwei Yang,et al.  SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix , 2006, International journal of cancer.

[28]  D. Morton,et al.  Estrogen receptor-alpha methylation predicts melanoma progression. , 2006, Cancer research.

[29]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Elashoff,et al.  Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Giuliano,et al.  Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer , 2005, Oncogene.

[32]  G. Watkins,et al.  Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[33]  W. Frankel,et al.  Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles , 2004, Oncogene.

[34]  M. Colombo,et al.  Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma , 2003, The Journal of experimental medicine.

[35]  E Helene Sage,et al.  Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. , 2003, Cancer research.

[36]  R. Brekken,et al.  Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. , 2003, The Journal of clinical investigation.

[37]  N. Lemke,et al.  Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. , 2002, Cancer research.

[38]  M. Castellazzi,et al.  Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells , 2002, Oncogene.

[39]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[40]  Alexander Marks,et al.  Monoclonal Antibody D2-40, a New Marker of Lymphatic Endothelium, Reacts with Kaposi's Sarcoma and a Subset of Angiosarcomas , 2002, Modern Pathology.

[41]  H. Kanayama,et al.  Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. , 2001, The Journal of urology.

[42]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[43]  E. Sage,et al.  SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. , 2001, The Journal of clinical investigation.

[44]  R. Brekken,et al.  SPARC, a matricellular protein: at the crossroads of cell-matrix communication. , 2001, Matrix biology : journal of the International Society for Matrix Biology.

[45]  E. Sage,et al.  SPARC, a Matricellular Glycoprotein with Important Biological Functions , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[46]  D. Massi,et al.  Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. , 1999, Human pathology.

[47]  E. Sage,et al.  SPARC (BM-40, Osteonectin) Inhibits the Mitogenic Effect of Vascular Endothelial Growth Factor on Microvascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[48]  Y. Chung,et al.  Prognostic value of angiogenesis in gastro-intestinal tumours. , 1996, European journal of cancer.

[49]  E. A. Everitt,et al.  SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix , 1989, The Journal of cell biology.